File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Oral Chlorambucil for Extranodal, Marginal Zone, B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue of the Orbit

TitleOral Chlorambucil for Extranodal, Marginal Zone, B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue of the Orbit
Authors
Issue Date2006
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/ophtha
Citation
Ophthalmology, 2006, v. 113 n. 7, p. 1209-1213 How to Cite?
AbstractPurpose: To report the outcome of oral chlorambucil as a single treatment in patients with orbital mucosa-associated lymphoid tissue (MALT) lymphoma. Design: Retrospective nonrandomized clinical study. Participants: Thirty-three patients with isolated orbital MALT lymphoma. Methods: Medical records of all patients with histology-verified orbital MALT lymphoma treated with oral chlorambucil at the Royal Melbourne Hospital were reviewed. Main Outcome Measures: Complete clinical response, partial response, local relapse, systemic extension (distant relapse), and survival. Results: Thirty-three patients (19 female; mean age, 69 years) participated in the study. Patients received an average of 4 courses of oral chlorambucil with a mean total dose of 600 mg. The lacrimal gland was the most frequent site of occurrence (24%), followed by the conjunctiva, eyelid, and superior orbit. Orbital mass, swelling, and diplopia were common presenting signs. Complete response was noted in 26 patients (79%). In 2 of the patients with complete clinical response, mild residual thickening was noted on follow-up orbital imaging studies. Four patients (12%) showed disease recurrence or relapse. Mean follow-up time was 32 (±20) months (range, 8 months-6 years; median, 26 months). None of the patients developed granulocytopenia secondary to chemotherapy, and none suffered significant nausea or vomiting. One patient with malignant transformation died 12 months after diagnosis and initial treatment. Conclusions: Systemic chemotherapy with chlorambucil is a reasonable option in patients with orbital MALT lymphoma. It is associated with minimal to no side effects. Additionally, it may be well tolerated by elderly patients and also may treat subclinical disease elsewhere. © 2006 American Academy of Ophthalmology.
Persistent Identifierhttp://hdl.handle.net/10722/183505
ISSN
2015 Impact Factor: 6.75
2015 SCImago Journal Rankings: 4.745
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorBen Simon, GJen_US
dc.contributor.authorCheung, Nen_US
dc.contributor.authorMckelvie, Pen_US
dc.contributor.authorFox, Ren_US
dc.contributor.authorMcnab, AAen_US
dc.date.accessioned2013-05-28T06:14:13Z-
dc.date.available2013-05-28T06:14:13Z-
dc.date.issued2006en_US
dc.identifier.citationOphthalmology, 2006, v. 113 n. 7, p. 1209-1213en_US
dc.identifier.issn0161-6420en_US
dc.identifier.urihttp://hdl.handle.net/10722/183505-
dc.description.abstractPurpose: To report the outcome of oral chlorambucil as a single treatment in patients with orbital mucosa-associated lymphoid tissue (MALT) lymphoma. Design: Retrospective nonrandomized clinical study. Participants: Thirty-three patients with isolated orbital MALT lymphoma. Methods: Medical records of all patients with histology-verified orbital MALT lymphoma treated with oral chlorambucil at the Royal Melbourne Hospital were reviewed. Main Outcome Measures: Complete clinical response, partial response, local relapse, systemic extension (distant relapse), and survival. Results: Thirty-three patients (19 female; mean age, 69 years) participated in the study. Patients received an average of 4 courses of oral chlorambucil with a mean total dose of 600 mg. The lacrimal gland was the most frequent site of occurrence (24%), followed by the conjunctiva, eyelid, and superior orbit. Orbital mass, swelling, and diplopia were common presenting signs. Complete response was noted in 26 patients (79%). In 2 of the patients with complete clinical response, mild residual thickening was noted on follow-up orbital imaging studies. Four patients (12%) showed disease recurrence or relapse. Mean follow-up time was 32 (±20) months (range, 8 months-6 years; median, 26 months). None of the patients developed granulocytopenia secondary to chemotherapy, and none suffered significant nausea or vomiting. One patient with malignant transformation died 12 months after diagnosis and initial treatment. Conclusions: Systemic chemotherapy with chlorambucil is a reasonable option in patients with orbital MALT lymphoma. It is associated with minimal to no side effects. Additionally, it may be well tolerated by elderly patients and also may treat subclinical disease elsewhere. © 2006 American Academy of Ophthalmology.en_US
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/ophthaen_US
dc.relation.ispartofOphthalmologyen_US
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAntineoplastic Agents, Alkylating - Adverse Effects - Therapeutic Useen_US
dc.subject.meshChlorambucil - Adverse Effects - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLymphoma, B-Cell, Marginal Zone - Drug Therapy - Mortality - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOrbital Neoplasms - Drug Therapy - Mortality - Pathologyen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshSurvival Rateen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleOral Chlorambucil for Extranodal, Marginal Zone, B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue of the Orbiten_US
dc.typeArticleen_US
dc.identifier.emailCheung, N: dannycheung@hotmail.comen_US
dc.identifier.authorityCheung, N=rp01752en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.ophtha.2006.01.057en_US
dc.identifier.pmid16647129-
dc.identifier.scopuseid_2-s2.0-33745380548en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33745380548&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume113en_US
dc.identifier.issue7en_US
dc.identifier.spage1209en_US
dc.identifier.epage1213en_US
dc.identifier.isiWOS:000238727400024-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridBen Simon, GJ=6701801401en_US
dc.identifier.scopusauthoridCheung, N=8054683900en_US
dc.identifier.scopusauthoridMcKelvie, P=7007081907en_US
dc.identifier.scopusauthoridFox, R=7403466862en_US
dc.identifier.scopusauthoridMcNab, AA=7005498604en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats